Company: CERO
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001213900-25-079898
Chunk: 210

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 8
Chunk 210
---
447,000 during the three months ended June 30, 2024 as compared
to $0 during the three months ended June 30, 2025, and (3) the recording of stock-based inducement expense of $707,300 during the three
months ended June 30, 2025 related to the conversion of Series C Preferred Stock as compared to $0 during the three months ended June
30, 2024. These negative changes in other expenses, net were offset by the recording of other expense of $631,000 during the three months
ended June 30, 2024 related to registration rights penalties recorded compared to $0 during the three months ended June 30, 2025, and
an increase in interest income, net of $30,000.

Net
loss and net loss attributable to common stockholders

For the three months ended
June 30, 2025 and 2024, net loss amounted to $5,417,000 and $2,449,000, respectively, which represents an increase in net loss of $2,968,000,
or 121.2%. During the three months ended June 30, 2025, in connection with our Series A, Series B and Series C preferred stock conversions,
we recorded deemed dividends of $24,700,000. Accordingly, for the three months ended June 30, 2025 and 2024, net loss attributable to
common stockholders amounted to $30,117,000, or $(61.71) per common share, and $2,449,000, or $(302.32) per common share, respectively.

Results
of Operations for the Six Months Ended June 30, 2025 and 2024

The
results of operations for the six months ended June 30, 2024 are pro forma as the period presented in the following table and
discussion includes the Predecessor for the period from January 1, 2024 through February 13, 2024 and the Company for the period from
February 14, 2024 through June 30, 2024. This pro forma period from January 1, 2024 to June 30, 2024 does not include the Merger transactions
that occurred on-the-line.

    For the Six Months Ended  June 30,  

    2024  

    2025 (Successor)  
    (Pro forma) (Pre